Patients with metastatic transitional cell carcinoma (TCC) have a median survival of 3 months if untreated (Babaian et al., 1980) . During the 1970's a number of cytotoxic agents were investigated for their efficacy in treating patients with advanced TCC. When used as single agents overall response rates of between 16 and 35% were consistently reported for cisplatin, methotrexate, cyclophosphamide, doxorubicin, 5-fluorouracil, and vinblastine (Yagoda et al., 1980) . However complete responses were rare and response durations brief.
In 1981 investigators from the Northern California Oncology Group (NCOG) began a phase II study in patients with metastatic transitional cell carcinoma of a chemotherapy combination comprising cisplatin, methotrexate and vinblastine (CMV). They reported on the first 60 patients entered into this study in 1985 (Harker et al., 1985) and documented a complete response rate of 28% with an overall median survival of 8 months. In 1983 the Memorial Hospital in New York began treating patients with advanced TCC with M-VAC combination chemotherapy which incorporated four of the most active single agents -methotrexate, vinblastine, doxorubicin and cisplatin. They reported their initial series in 1985 (Sternberg et al., 1985) and have since added to and updated their experience (Sternberg et al., 1988; Sternberg et al., 1989) . They have consistently reported encouraging clinical complete response rates of between 26% and 48% and in their most recent report the median survival for the whole group was 13 months with an estimated probability of 4-year survival of 18% +/-7% (Sternberg et al., 1989 All patients were assessed by physical examination, full blood count, biochemistry screen, liver function tests, chest x-ray and abdominal ultrasound. In addition most patients underwent computerised tomographic (CT) scanning of the abdomen and pelvis; isotope bone scanning was performed in patients with skeletal symptoms.
All patients had leukocyte counts greater than 3.5 x 109 1'1 neutrophil counts greater than 2.0 x 1091à nd platelet counts greater than 150 x I09 -at the time of commencing chemotherapy. The creatinine clearance was calculated according to the formula of Cockcroft and Gault (1976) and only patients with a creatinine clearance of greater than 50 ml min ' were eligible to receive CMV chemotherapy. Patients with hydronephrosis and levels of renal impairment precluding CMV chemotherapy had nephrostomy tubes inserted in an effort to improve renal function and make them eligible for CMV treatment.
Patients were treated as outlined in Table II . The day 1 and 8 treatments were given as an outpatient and on day 2 patients were admitted to hospital and prehydrated with intravenous normal saline. When urine flow was greater than 150 ml h'-I cisplatin was given by 30 min infusion. Treatment was recycled on day 22 for a total of six cycles unless there was evidence of progressive disease or intolerable treatment side-effects. Drug doses were modified according to blood counts and renal function as outlined in Table II . Seven patients at the end of the study period received cisplatin at a dose of 70 mg m2 from the outset in an attempt to limit cisplatin toxicity. Only one patient underwent postchemotherapy surgery, at which a retroperitoneal mass was resected. No residual tumour was apparent -despite this the patient relapsed again at this site.
A complete response was defined as complete resolution of all radiological and clinical evidence of disease as assessed 1 month after the completion of chemotherapy. Partial response was defined as a 50% or greater reduction in the diameter of all tumour masses evident clinically and radiologically and was the best response recorded at any time during or immediately after chemotherapy.
Survival was calculated from the date of first chemotherapy until the date of last follow-up or death.
Results
Thirty-three patients had measurable disease. Of the remaining ten patients, six had pelvic recurrence visualised on CT which which was not measurable, three had bone metastases and no other measurable disease and one patient received chemotherapy for histologically positive surgical resection margins after cystectomy. Eight of the patients with measurable disease achieved a complete response (24%) and 11 patients achieved a partial response (34%) for an overall response rate of 58%. One of the three patients with bone metastases as the only metastatic site had complete resolution of all symptoms and return to normal of the alkaline phosphatase level. Of the 33 patients with bladder primaries five (15%) achieved CR compared with three (30%) out of ten patients with non-bladder primaries. Six (35%) out of 17 patients with disease confined to nodal metastatic sites achieved CR compared with only two (12%) out of 17 patients with measurable parenchymal (lung, liver, bone) metastases. The median duration of CR was 6 months (range 1-20 + months).
The median survival duration for patients achieving CR was 13 months (range 5-29 + months). Three patients are still alive, however only two are progression free 19 and 27 months after completing chemotherapy. Figure 1 shows the survival curve of all 43 patients receiving CMV chemotherapy. Figure 2 illustrates the survival of patients grouped according to whether their metastases were nodal only or parenchymal (six patients with locally extensive disease alone are excluded). Figure 3 shows the survival curves for patients with bladder and non-bladder primaries.
Patients received a median of five cycles of chemotherapy (range 1-6); 19 patients (43%) received a full six cycles of chemotherapy. Of these 19 patients only 11 (58%) had six cycles of cisplatin. One patient refused further chemotherapy after one cycle of CMV and 23 patients stopped chemotherapy prematurely because of unresponsive or progressive disease. We included ten patients in our report who did not have measurable disease. The difficulties in radiological assessment of disease in the pelvis accounted for most of these cases. Other groups have similarly included significant numbers of such patients (Harker et al., 1985; Tannock et al., 1989) . We believe that this more accurately reflects the true patient population with advanced TCC. In comparison the M-VAC series from the Memorial Hospital included only three such C) C MI .)
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.1 E CMV CHEMOTHERAPY FOR ADVANCED TRANSITIONAL CELL CARCINOMA 545 patients out of a total of 133 (Stemnberg et al., 1989 ). In our series those patients with locally advanced non-measurable disease had an inferior outcome compared with the rest of the group (median survival 5 months; range 1-16 months). To have excluded them from our series would have artifically raised the median survival. Whether patients with locally infiltrative (but unmeasurable) disease in the pelvis have an inherently worse outlook than those with more distant metastases is unknown although similar observations have been made in the chemotherapy of advanced cervical carcinoma (Potter et al., 1989) .
Our overall results are remarkably similar to those reported by Harker et al. (1985) who first reported the use of CMV chemotherapy for this condition. The results are not as impressive as the M-VAC data from the Memorial Hospital (Stemnberg et al., 1989) but comparisons between different patient populations and treatments are not possible. In fact data on M-VAC and CMV from other centres is surprisingly sparse; one group however has been unable to reproduce the high response rates to M-VAC reported by the Memorial Hospital (Tannock et al., 1989) .
CMV proved a toxic regimen in our treatment population. Three early deaths were probably treatment related but no definitive proof was available. Toxic deaths have been reported in other series in approximately 2-4% of cases (Harker et al., 1985; Hillcoat et al., 1989; Logothetis et al., 1990a; Stemnberg et al., 1989; Tannock et al., 1989) .
Too few randomised studies of sufficient size have been conducted to direct oncologists in the choice of treatment for advanced TCC, and most of these have been performed on the assumption that cisplatin is the superior drug for this condition. The National Bladder Cancer Collaborative Group compared cisplatin with cisplatin and cyclophosphamide in a randomised trial and 131 patients were entered (Soloway et al., 1983) . No significant differences in response or survival were noted between the two groups but a study of this size was unlikely to reveal anything other than large treatment differences. Similarly the Southeastern Cancer Study Group Trial (Troner et al., 1987) showed no differences between cisplatin alone and cisplatin, doxorubicin and cyclophosphamide in combination (116 patients entered). Hillcoat et al. (1989) compared cisplatin alone with cisplatin plus methotrexate and reported no significant differences. The study was small (108 patients) and the potential for missing significant treatment differences was again noted (Scher, 1989) .
A randomised study between M-VAC and CISCA (cisplatin, cyclophosphamide and doxorubicin) performed at the M.D. Anderson Cancer Center revealed a significant difference in response rates and overall median survival in favour of the MVAC group (Logothetis et al., 1990a) . A randomised comparison of cisplatin alone versus M-VAC has been reported in abstract form (Loehrer et al., 1990) . A significant difference in response rate (9% versus 33%) in favour of M-VAC and a 4 month prolongation of median survival was reported. Whether the absence of doxorubicin from the CMV regimen and doxorubicin and methotrexate from the CISCA regimen can explain the superior results for M-VAC in these trials is unknown. No randomised study has been performed between CMV and M-VAC.
Future directions in the management of advanced TCC remain to be defined. Accepting the toxicity of cisplatinbased chemotherapy becomes questionable when long-term survivors are rare. In the randomised studies above the overall response rates to cisplatin alone were only 16%, 20% and 31% respectively (Troner et al., 1987; Hillcoat et al., 1989; Soloway et al., 1983) . What is beyond question is that cisplatin is the drug responsible for the most toxicity. In the absence of new active agents for TCC and considering the relatively small numbers of long-term survivors after chemotherapy one approach to the problem is to attempt to minimise the toxicity of the treatment thereby making it available to more patients. With this view in mind the MRC Advanced Bladder Cancer Subgroup from Great Britain have launched a randomised trial comparing the CMV regimen (cisplatin dose 70 mg m-2) with the same chemotherapy without the cisplatin (MV).
Even in the event that the CMV regimen were found to be superior to MV it may still be prudent to confine CMV treatment to patients with an inherently better outcome. Younger patients with good performance status could be selected for the more intensive treatment. Other prognostic factors could be utilised to determine those patients with a higher probability of achieving a complete response and possible long-term survival. In our series those patients with non-bladder primaries and disease confined to nodal metastatic sites had a significantly longer median survival. However these results should be interpreted with caution in view of the small numbers involved in the analysis. Larger trials are needed to test these prognostic factors and produce new indicators of treatment outcome.
Another approach adopted by the M.D. Anderson group is to dose intensify the chemotherapy using haemopoietic growth factors. They reported impressive response rates with escalated M-VAC chemotherapy supported by G-CSF in patients who were primarily resistant to or relapsing from combination chemotherapy (Logothetis et al., 1990b) . However platelet toxicity in that study was profound and this approach may not be widely applicable.
The results of ongoing randomised trials will hopefully provide practical recommendations for oncologists who manage patients with this common malignancy which is chemosensitive but largely incurable.
